Claims for Patent: 8,013,002

Summary for Patent: 8,013,002

Title:	Methods of administering pirfenidone therapy
Abstract:	The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
Inventor(s):	Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA)
Assignee:	Intermune, Inc. (Brisbane, CA)
Application Number:	13/049,894
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,013,002
Patent Claims:	1. A method of administering pirfenidone and fluvoxamine concurrently to a patient in need thereof comprising administering a therapeutically effective amount of fluvoxamine to the patient and administering a therapeutically effective amount of pirfenidone to the patient, wherein the amount of the pirfenidone is about 801 mg/day. 2. The method of claim 1 wherein the pirfenidone is administered three times per day. 3. The method of claim 2 wherein the patient has idiopathic pulmonary fibrosis (IPF). 4. The method of claim 3 wherein the pirfenidone is administered to the patient with food. 5. The method of claim 1 further comprising discontinuing co-administration of fluvoxamine and administering a therapeutically effective amount of pirfenidone. 6. A method of providing pirfenidone therapy to a patient in need thereof comprising titrating the dosage of pirfenidone administered to the patient downward from a dose of about 2400 mg/day, while co-administering fluvoxamine, wherein the dose of pirfenidone is reduced by about 1600 mg/day. 7. The method of claim 6 wherein about 800 mg/day of pirfenidone is administered to the patient. 8. The method of claim 6 wherein the pirfenidone is administered three times per day. 9. The method of claim 8 wherein the patient has idiopathic pulmonary fibrosis (IPF). 10. The method of claim 9 wherein the pirfenidone is administered to the patient with food. 11. The method of claim 6 further comprising discontinuing co-administration of fluvoxamine and administering about 2400 mg/day of pirfenidone.